RE:RE:RE:Resistance to ADCs in the treatment of solid tumors
[ NICE effectively implied that despite the reported improvement in OS and PFS Enhertu, the categorization of the ADC could not be expanded beyond HER2-positive, nothwithstanding approval of the HER2-low/ultralow re-categorization in the US and Japan, for example ]
The assays and methods currently used to determine HER2 status are arguably not sensitive enough to get regulators on board with such a paradigm shift. And even to kickstart that debate the Destiny-Breast06 HER2-ultralow subgroup will have to show very little divergence from the HER2-low population, according to contemporary current opinions.